This timeline shows how the investigation on cervical cancer has progressed since the 1950s.
Created by cancerscreeningproject on 08/05/2011
Last updated: 10/06/11 at 19:10
Tags: cervical cancer screening HPV research
Research shows substantial reductions in cervical cancer can be anticipated by vaccination, but most of the benefit will not be apparent for at least another decade. High vaccine coverage is the key factor for achieving these benefits.
The US Food and Drugs Administration licensed the Cervarix vaccine for use in girls and women aged between 10 and 25 years old.
Research carried out by Cancer Research UK shows links between cervical cancer and hormonal contraceptives.
The European Medicines Agency approved the Cervarix vaccine, from UK's GlaxoSmithKline, for use in the European Union.
The European Medicines Agency considered that the risk-benefit balance of the Gardasil vaccine was favourable and therefore recommended the granting of the marketing authorisation.
The US Food and Drug Administration licenses Gardasil, a vaccine for prevention of cervical cancer and other diseases in females caused by the human papillomavirus (HPV).
Scientists have calculated that the cervical screening programme has prevented an epidemic that would have killed about one in 65 of all British women born since 1950 and culminated in about 6000 deaths per year in the UK. 80% or more of these deaths are likely to be prevented by screening.
Research shows HPV testing could be used for primary screening in women older than 30 years, with cytology used to triage HPV-positive women.
Lifestyle factors are linked to HPV infection and cervical cancer, particularly smoking, having a high number of sexual partners and starting to have sex at a younger age.
Research shows that the human papillomavirus (HPV) is the prime cause of cervical cancer worldwide.
Proteins called MCMs are found at high levels in cervical cancer (and other types of cancer). Clinical trials follow to see if testing for MCM proteins can increase the effectiveness of screening.
The results of a study allow the choice between two different types of antiviral vaccination.
UK introduces a computerised call and recall system, ensuring that all eligible women could benefit from screening.
Researchers carried out some of the earliest studies of cervical screening in the UK, laying the foundations for the screening programme we have today.